Darragh Twomey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Recognitions
Darragh Twomey has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Prashanthan Sanders
Centre for Heart Rhythm Disorders, Adelaide University and Royal Adelaide Hospital, Adelaide, Australia
19 shared publications - Dennis H. Lau
Australian Dysautonomia and Arrhythmia Research Collaborative, The University of Adelaide, Adelaide, SA, Australia; South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Department of Cardiology, Royal Adelaide Hospital, Adelaide, SA, Australia
17 shared publications - Rajiv Mahajan
School of Medicine, College of Health, Adelaide University, South Australia, Australia; South Australian Health and Medical Research Institute (SAHMRI), South Australia, Australia; Lyell McEwin Hospital, Northern Adelaide Local Health Network, South Australia, Australia
12 shared publications - Melissa E. Middeldorp
Centre for Heart Rhythm Disorders Adelaide University Adelaide Australia
10 shared publications - Rajeev Kumar Pathak
Australian National University, Canberra, Australian Capital Territory, Australia; Canberra Heart Rhythm Centre, Canberra, Australian Capital Territory, Australia
9 shared publications Jonathan M. Kalman
Department of Cardiology, Royal Melbourne Hospital, Melbourne, Australia; Department of Medicine, University of Melbourne, Melbourne, Australia
6 shared publications
Latest Publications
- Open Access
- 14 December 2021
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2021 (12)
Catheter ablation versus escalation of antiarrhythmic medications for management of ventricular tachycardia in patients with ischaemic heart disease
Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess and compare the effects of catheter ablation for ventricular tachycardia (VT) with escalation of antiarrhythmic drugs (AADs) in patients with ischaemic heart disease (IHD).
- 14 December 2021
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2021 (12)
Open AccessCatheter ablation versus escalation of antiarrhythmic medications for management of ventricular tachycardia in patients with ischaemic heart disease
Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess and compare the effects of catheter ablation for ventricular tachycardia (VT) with escalation of antiarrhythmic drugs (AADs) in patients with ischaemic heart disease (IHD).
- Open Access
- 1 February 2021
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 117 (7) , 1746-1759
NLRP3 inflammasome is a key driver of obesity-induced atrial arrhythmias
Obesity, an established risk factor of atrial fibrillation (AF), is frequently associated with enhanced inflammatory response. However, whether inflammatory signaling is causally linked to AF pathogenesis in obesity remains elusive. We recently demonstrated that the constitutive activation of the ‘NACHT, LRR, and PYD Domains-containing Protein 3’ (NLRP3) inflammasome promotes AF susceptibility. In this study, we hypothesized that the NLRP3 inflammasome is a key driver of obesity-induced AF. Western blotting was performed to determine the level of NLRP3 inflammasome activation in atrial tissues of obese patients, sheep, and diet-induced obese (DIO) mice. The increased body weight in patients, sheep, and mice was associated with enhanced NLRP3-inflammasome activation. To determine whether NLRP3 contributes to the obesity-induced atrial arrhythmogenesis, wild-type (WT) and NLRP3 homozygous knockout (NLRP3−/−) mice were subjected to high-fat-diet (HFD) or normal chow (NC) for 10 weeks. Relative to NC-fed WT mice, HFD-fed WT mice were more susceptible to pacing-induced AF with longer AF duration. In contrast, HFD-fed NLRP3−/− mice were resistant to pacing-induced AF. Optical mapping in DIO mice revealed an arrhythmogenic substrate characterized by abbreviated refractoriness and action potential duration (APD), two key determinants of reentry-promoting electrical remodeling. Upregulation of ultra-rapid delayed-rectifier K+-channel (Kv1.5) contributed to the shortening of atrial refractoriness. Increased profibrotic signaling and fibrosis along with abnormal Ca2+ release from sarcoplasmic reticulum (SR) accompanied atrial arrhythmogenesis in DIO mice. Conversely, genetic ablation of Nlrp3 (NLRP3−/−) in HFD-fed mice prevented the increases in Kv1.5 and the evolution of electrical remodeling, the upregulation of profibrotic genes, and abnormal SR Ca2+ release in DIO mice. These results demonstrate that the atrial NLRP3 inflammasome is a key driver of obesity-induced atrial arrhythmogenesis and establishes a mechanistic link between obesity-induced AF and NLRP3-inflammasome activation.
- 1 February 2021
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 117 (7) , 1746-1759
Open AccessNLRP3 inflammasome is a key driver of obesity-induced atrial arrhythmias
Obesity, an established risk factor of atrial fibrillation (AF), is frequently associated with enhanced inflammatory response. However, whether inflammatory signaling is causally linked to AF pathogenesis in obesity remains elusive. We recently demonstrated that the constitutive activation of the ‘NACHT, LRR, and PYD Domains-containing Protein 3’ (NLRP3) inflammasome promotes AF susceptibility. In this study, we hypothesized that the NLRP3 inflammasome is a key driver of obesity-induced AF. Western blotting was performed to determine the level of NLRP3 inflammasome activation in atrial tissues of obese patients, sheep, and diet-induced obese (DIO) mice. The increased body weight in patients, sheep, and mice was associated with enhanced NLRP3-inflammasome activation. To determine whether NLRP3 contributes to the obesity-induced atrial arrhythmogenesis, wild-type (WT) and NLRP3 homozygous knockout (NLRP3−/−) mice were subjected to high-fat-diet (HFD) or normal chow (NC) for 10 weeks. Relative to NC-fed WT mice, HFD-fed WT mice were more susceptible to pacing-induced AF with longer AF duration. In contrast, HFD-fed NLRP3−/− mice were resistant to pacing-induced AF. Optical mapping in DIO mice revealed an arrhythmogenic substrate characterized by abbreviated refractoriness and action potential duration (APD), two key determinants of reentry-promoting electrical remodeling. Upregulation of ultra-rapid delayed-rectifier K+-channel (Kv1.5) contributed to the shortening of atrial refractoriness. Increased profibrotic signaling and fibrosis along with abnormal Ca2+ release from sarcoplasmic reticulum (SR) accompanied atrial arrhythmogenesis in DIO mice. Conversely, genetic ablation of Nlrp3 (NLRP3−/−) in HFD-fed mice prevented the increases in Kv1.5 and the evolution of electrical remodeling, the upregulation of profibrotic genes, and abnormal SR Ca2+ release in DIO mice. These results demonstrate that the atrial NLRP3 inflammasome is a key driver of obesity-induced atrial arrhythmogenesis and establishes a mechanistic link between obesity-induced AF and NLRP3-inflammasome activation.
- 1 August 2019
- Published by Elsevier in Heart Rhythm
- Vol. 16 (8) , 1204-1214
Implication of ventricular pacing burden and atrial pacing therapies on the progression of atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials
- 1 August 2019
- Published by Elsevier in Heart Rhythm
- Vol. 16 (8) , 1204-1214
Implication of ventricular pacing burden and atrial pacing therapies on the progression of atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials
- 1 May 2019
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 5 (5) , 635-636
Left Ventricular Endocardial Pacing With a Novel Wireless CRT System Pacing Threshold Trend
- 1 May 2019
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 5 (5) , 635-636
Left Ventricular Endocardial Pacing With a Novel Wireless CRT System Pacing Threshold Trend
- 1 December 2018
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 4 (12) , 1529-1540
Electroanatomical Remodeling of the Atria in Obesity
- 1 December 2018
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 4 (12) , 1529-1540
Electroanatomical Remodeling of the Atria in Obesity
- Top Cited Papers
- 14 June 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (12) , 1929-1935
PREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study
Atrial fibrillation (AF) is a progressive disease. Obesity is associated with progression of AF. This study evaluates the impact of weight and risk factor management (RFM) on progression of the AF. As described in the Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up (LEGACY) Study, of 1415 consecutive AF patients, 825 had body mass index ≥ 27 kg/m2 and were offered weight and RFM. After exclusion, 355 were included for analysis. Weight loss was categorized as: Group 1 (P = NS). In Group 1, 41% progressed from paroxysmal to persistent and 26% from persistent to paroxysmal or no AF. In Group 2, 32% progressed from paroxysmal to persistent and 49% reversed from persistent to paroxysmal or no AF. In Group 3, 3% progressed to persistent and 88% reversed from persistent to paroxysmal or no AF (P < 0.001). Increased weight loss was significantly associated with greater AF freedom: 45 (39%) in Group 1, 69 (67%) in Group 2, and 116 (86%) in Group 3 (P ≤ 0.001). Obesity is associated with progression of the AF disease. This study demonstrates the dynamic relationship between weight/risk factors and AF. Weight-loss management and RFM reverses the type and natural progression of AF.
- 14 June 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (12) , 1929-1935
Top Cited PapersPREVEntion and regReSsive Effect of weight-loss and risk factor modification on Atrial Fibrillation: the REVERSE-AF study
Atrial fibrillation (AF) is a progressive disease. Obesity is associated with progression of AF. This study evaluates the impact of weight and risk factor management (RFM) on progression of the AF. As described in the Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up (LEGACY) Study, of 1415 consecutive AF patients, 825 had body mass index ≥ 27 kg/m2 and were offered weight and RFM. After exclusion, 355 were included for analysis. Weight loss was categorized as: Group 1 (P = NS). In Group 1, 41% progressed from paroxysmal to persistent and 26% from persistent to paroxysmal or no AF. In Group 2, 32% progressed from paroxysmal to persistent and 49% reversed from persistent to paroxysmal or no AF. In Group 3, 3% progressed to persistent and 88% reversed from persistent to paroxysmal or no AF (P < 0.001). Increased weight loss was significantly associated with greater AF freedom: 45 (39%) in Group 1, 69 (67%) in Group 2, and 116 (86%) in Group 3 (P ≤ 0.001). Obesity is associated with progression of the AF disease. This study demonstrates the dynamic relationship between weight/risk factors and AF. Weight-loss management and RFM reverses the type and natural progression of AF.
- 10 January 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (16) , 1407-1415
Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis
To determine stroke risk in subclinical atrial fibrillation (AF) and temporal association between subclinical AF and stroke. Pubmed/Embase was searched for studies reporting stroke in subclinical AF in patients with cardiac implantable electronic devices (CIEDs). After exclusions, 11 studies were analysed. Of these seven studies reported prevalence of subclinical AF, two studies reported association between subclinical and clinical AF, seven studies reported stroke risk in subclinical AF, and five studies reported temporal relationship between subclinical AF and stroke. Subclinical AF was noted after CIEDs implant in 35% [interquartile range (IQR) 34-42] of unselected patients with pacing indication over 1-2.5 years. The definition and cut-off duration (for stroke risk) of subclinical AF varied across studies. Subclinical AF was strongly associated with clinical AF (OR 5.7, 95% CI 4.0-8.0, P < 0.001, I2 = 0%). The annual stroke rate in patients with subclinical AF > defined cut-off duration was 1.89/100 person-year (95% CI 1.02-3.52) with 2.4-fold (95% CI 1.8-3.3, P < 0.001, I2 = 0%) increased risk of stroke as compared to patients with subclinical AF < cut-off duration (absolute risk was 0.93/100 person-year). Three studies provided mean CHADS2 score. In these studies, with mean CHADS2 score of 2.1 ± 0.1, subclinical AF was associated with annual stroke rate of 2.76/100 person-years (95% CI 1.46-5.23). After excluding patients without AF, only 17% strokes occurred in presence of ongoing AF. Subclinical AF was noted in 29% [IQR 8-57] within 30 days preceding stroke. Subclinical AF strongly predicts clinical AF and is associated with elevated absolute stroke risk albeit lower than risk described for clinical AF.
- 10 January 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (16) , 1407-1415
Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis
To determine stroke risk in subclinical atrial fibrillation (AF) and temporal association between subclinical AF and stroke. Pubmed/Embase was searched for studies reporting stroke in subclinical AF in patients with cardiac implantable electronic devices (CIEDs). After exclusions, 11 studies were analysed. Of these seven studies reported prevalence of subclinical AF, two studies reported association between subclinical and clinical AF, seven studies reported stroke risk in subclinical AF, and five studies reported temporal relationship between subclinical AF and stroke. Subclinical AF was noted after CIEDs implant in 35% [interquartile range (IQR) 34-42] of unselected patients with pacing indication over 1-2.5 years. The definition and cut-off duration (for stroke risk) of subclinical AF varied across studies. Subclinical AF was strongly associated with clinical AF (OR 5.7, 95% CI 4.0-8.0, P < 0.001, I2 = 0%). The annual stroke rate in patients with subclinical AF > defined cut-off duration was 1.89/100 person-year (95% CI 1.02-3.52) with 2.4-fold (95% CI 1.8-3.3, P < 0.001, I2 = 0%) increased risk of stroke as compared to patients with subclinical AF < cut-off duration (absolute risk was 0.93/100 person-year). Three studies provided mean CHADS2 score. In these studies, with mean CHADS2 score of 2.1 ± 0.1, subclinical AF was associated with annual stroke rate of 2.76/100 person-years (95% CI 1.46-5.23). After excluding patients without AF, only 17% strokes occurred in presence of ongoing AF. Subclinical AF was noted in 29% [IQR 8-57] within 30 days preceding stroke. Subclinical AF strongly predicts clinical AF and is associated with elevated absolute stroke risk albeit lower than risk described for clinical AF.
- 15 December 2017
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (FI_3) , f366-f376
Outcomes of persistent and long-standing persistent atrial fibrillation ablation: a systematic review and meta-analysis
Several techniques have been utilized for the ablation of persistent (P) and long-standing persistent (LsP) atrial fibrillation (AF); however, the best approach of substrate ablation remains poorly defined. This study aims to examine the impact of ablation approach on outcomes associated with P or LsP AF ablation by conducting a meta-analysis and regression on contemporary literature. A systematic literature review was conducted up to 29 July 2015 for scientific literature reporting on outcomes associated with P or LsP AF ablation. One hundred and thirteen studies reported outcomes in a total of 18 657 patients undergoing various ablation approaches for the treatment of P–LsP AF between 2001 and 2015. The point efficacy estimate of a single-AF ablation procedure without the use of anti-arrhythmic drugs was 43% (95% CI; 39–47%). Multiple procedures and/or the use of anti-arrhythmic drugs increase success to 69% (95% CI; 66–71%). Meta-regression revealed that ablation technique (P < 0.001) and left atrial size (P = 0.02) were predictive of single procedure, drug-free success. The addition of extra-pulmonary substrate approaches was associated with declining efficacy when compared to a pulmonary vein ablation alone. The efficacy of a single-AF ablation procedure for P or LsP AF is 43%; however, can be increased to 69% with the use of multiple procedures and/or anti-arrhythmic drugs. Current literature supports the finding that pulmonary vein antrum ablation/isolation is at least equivalently efficacious to other contemporary P–LsP ablation strategies.
- 15 December 2017
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 20 (FI_3) , f366-f376
Outcomes of persistent and long-standing persistent atrial fibrillation ablation: a systematic review and meta-analysis
Several techniques have been utilized for the ablation of persistent (P) and long-standing persistent (LsP) atrial fibrillation (AF); however, the best approach of substrate ablation remains poorly defined. This study aims to examine the impact of ablation approach on outcomes associated with P or LsP AF ablation by conducting a meta-analysis and regression on contemporary literature. A systematic literature review was conducted up to 29 July 2015 for scientific literature reporting on outcomes associated with P or LsP AF ablation. One hundred and thirteen studies reported outcomes in a total of 18 657 patients undergoing various ablation approaches for the treatment of P–LsP AF between 2001 and 2015. The point efficacy estimate of a single-AF ablation procedure without the use of anti-arrhythmic drugs was 43% (95% CI; 39–47%). Multiple procedures and/or the use of anti-arrhythmic drugs increase success to 69% (95% CI; 66–71%). Meta-regression revealed that ablation technique (P < 0.001) and left atrial size (P = 0.02) were predictive of single procedure, drug-free success. The addition of extra-pulmonary substrate approaches was associated with declining efficacy when compared to a pulmonary vein ablation alone. The efficacy of a single-AF ablation procedure for P or LsP AF is 43%; however, can be increased to 69% with the use of multiple procedures and/or anti-arrhythmic drugs. Current literature supports the finding that pulmonary vein antrum ablation/isolation is at least equivalently efficacious to other contemporary P–LsP ablation strategies.
- 8 May 2017
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 40 (6) , 624-628
Premature Trigger of ERI in Medtronic EnRhythm Devices
Medical technology has made significant advances over the last few decades with smaller and more dynamic pacemakers. However, technical failures leading to premature replacement is a cause of concern. We present a series of Medtronic EnRhythm devices that reached premature elective replacement indicator (ERI). The database of Centre of Heart Rhythm Disorders was searched for EnRhythm device implantation from 2006 to 2011. Battery depletion <8.5 years was considered premature considering the projected average longevity to be 8.5-10.5 years. An unexpected premature ERI was defined when it was reached within 3 months of last normal check. Device follow-up was 3 monthly after advisory. A total of 88 EnRhythm pacemakers were implanted. Over a median follow-up of 6.2 years (range: 0.3 – 9.2), 39 (44.3%) EnRhythm devices reached premature ERI. In 11 (28%), ERI was not recognized and patients were being investigated for other causes of unsteadiness or dyspnea prior to device check. Notably, 3 (7%) patients had premature ERI <3.5 years. 10 (25.6%) had sudden and unexpected premature ERI. While asynchronous pacing was observed there were no cases of absence of pacing. The rate of premature ERI for EnRhythm devices was 44.3%; significantly higher than reported by the manufacturer. Of concern, a sizeable proportion occurred unexpectedly, warranting more frequent reviews and empirical replacement in some patients. With the experience of the EnRhythm, appropriate monitoring strategies are recommended for future advisories. This article is protected by copyright. All rights reserved
- 8 May 2017
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 40 (6) , 624-628
Premature Trigger of ERI in Medtronic EnRhythm Devices
Medical technology has made significant advances over the last few decades with smaller and more dynamic pacemakers. However, technical failures leading to premature replacement is a cause of concern. We present a series of Medtronic EnRhythm devices that reached premature elective replacement indicator (ERI). The database of Centre of Heart Rhythm Disorders was searched for EnRhythm device implantation from 2006 to 2011. Battery depletion <8.5 years was considered premature considering the projected average longevity to be 8.5-10.5 years. An unexpected premature ERI was defined when it was reached within 3 months of last normal check. Device follow-up was 3 monthly after advisory. A total of 88 EnRhythm pacemakers were implanted. Over a median follow-up of 6.2 years (range: 0.3 – 9.2), 39 (44.3%) EnRhythm devices reached premature ERI. In 11 (28%), ERI was not recognized and patients were being investigated for other causes of unsteadiness or dyspnea prior to device check. Notably, 3 (7%) patients had premature ERI <3.5 years. 10 (25.6%) had sudden and unexpected premature ERI. While asynchronous pacing was observed there were no cases of absence of pacing. The rate of premature ERI for EnRhythm devices was 44.3%; significantly higher than reported by the manufacturer. Of concern, a sizeable proportion occurred unexpectedly, warranting more frequent reviews and empirical replacement in some patients. With the experience of the EnRhythm, appropriate monitoring strategies are recommended for future advisories. This article is protected by copyright. All rights reserved
- 1 May 2017
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 3 (5) , 436-447
Cost-Effectiveness and Clinical Effectiveness of the Risk Factor Management Clinic in Atrial Fibrillation
- 1 May 2017
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 3 (5) , 436-447
Cost-Effectiveness and Clinical Effectiveness of the Risk Factor Management Clinic in Atrial Fibrillation